What Is Lymphedema? What Causes Lymphedema?

Lymphedema, lymphoedema, or lymphatic obstruction is a chronic (long-term) condition in which excess fluid (lymph) collects in tissues causing edema (swelling). Lymphedema can be very debilitating. In short, lymphedema is edema due to lymphatic fluid; a blockage of the lymphatic system. The lymphatic system is an important part of our immune and circulatory systems… Read Full Article
readmore

FDA Approves Therapy To Treat Gaucher Disease

The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease. Gaucher disease occurs in people who do not produce enough of an enzyme called glucocerebrosidase… Read Full Article
readmore

Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients… Read Full Article
readmore

Shire Provides Update On Biologics License Application (BLA) Filing For REPLAGAL(R) (agalsidase Alfa) With The U.S. Food And Drug Administration (FDA)

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease. Shire filed a BLA for REPLAGAL in December 2009… Read Full Article
readmore

Photoacoustics Technology Could Make Some Lab Processes More Efficient, Says MU Researcher

Knowing the stage of a patient’s melanoma is important when choosing the best course of treatment. When the cancer has progressed to the lymph nodes, a more aggressive treatment is needed. Examining an entire lymph node for cancer takes much effort and time; a new technique might help make the process more efficient. University of Missouri researchers in the Christopher S… Read Full Article
readmore

Lymphedema: Risk Reduction And Management Strategies

There are no scientific studies showing that lymphedema can be prevented, but there are ways to lower your risk of developing this treatment side effect… Read Full Article
readmore

MU Researchers Collaborate To Develop Standard Of Care For Breast Cancer Survivors With Lymphedema

Lymphedema, a chronic swelling condition that can appear after breast cancer surgery, is a risk for 1.3 million breast cancer survivors. Although lymphedema can cause lifelong swelling in the arms, back, neck and chest, there is no national standard of diagnosis or care… Read Full Article
readmore

Shire Presents Positive Efficacy And Safety Data For Velaglucerase Alfa In Treatment Of Naive Patients With Type 1 Gaucher Disease

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease… Read Full Article
readmore

Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study Of Amigal(TM) For Fabry Disease

Amicus Therapeutics (Nasdaq: FOLD) announced additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigalâ„¢ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida… Read Full Article
readmore

Protalix Presents Additional Phase III Data For Taliglucerase Alfa At The WORLD Symposium

Protalix BioTherapeutics, Inc… Read Full Article
readmore
Page 1 of 812345»...Last »
line
footer
Copyright © 2009 The Cancer Foundation For The World Inc. A registered 501(c)3 Non-Profit public charity. || Privacvy Policy || Disclaimer